Plecanatide Research

Tanveer FS

Akram U, Ul Ain H, Ahmed S, Fatima E, Raza MA, Ahmad E et al.

Constipation is a common gastrointestinal disorder with limited effective treatments and a significant impact on quality of life. Plecanatide, a guanylate cyclase-C agonist, has shown promise in improving symptoms with a favorable safety profile. This meta-analysis aimed to evaluate the effective...

Brenner DM, Shin AS, Laitman AP, Deutsch JK, Kunkel DC

Irritable bowel syndrome with constipation (IBS-C) is characterized by multiple sensory symptoms, including abdominal pain, bloating, and bowel habit alterations. Therapeutic response should address all components. This study assesses a new exploratory trisymptom composite efficacy endpoint in an...

de Geus A, Gordon M, Sinopoulou V, Ajiboye A, Thornton AJ, Liu S et al.

There has been a substantial increase in studies on functional constipation in children as new therapies are deployed. We aimed to provide an up-to-date, methodologically robust systematic review and meta-analysis on the efficacy and safety of pharmacological therapies for functional constipation...

Lei D, Guo C, Zhao S

To analyze and evaluate adverse drug event (ADE) signals for two GC-C receptor agonists, Linaclotide and Plecanatide, thereby enhancing understanding of their clinical safety.Data on adverse reactions associated with Linaclotide and Plecanatide were extracted from the FDA Adverse Event Reporting ...

Colbran R, Neshatian L

Chronic constipation remains challenging to manage, particularly when lifestyle measures prove insufficient. With an expanding range of pharmacologic options available, clinicians face the task of choosing the right agent for the right patient. This review explores recent developments in prescrip...

Fan X, Li Y, Lin X

Linaclotide and plecanatide, as guanylate cyclase-C agonists, are effective treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation. While their therapeutic benefits are well-established, the potential association between these drugs and the adverse reaction ...

Jonker CAL, van Os TM, Gorter RR, Levitt MA, Benninga MA

In this review, we summarize current insights into the treatment of functional constipation (FC) in children. Constipation is a global issue in the pediatric population, with a prevalence of approximately 9.5%. Initial management involves a combination of non-pharmacological and pharmacological i...

Zhou Y, Jin J, Zhou P, Su W, Yao G

The principle of structure dictating properties is illustrated by the direct correlation between cyclic peptide conformation and their biological efficacy. Plecanatide, a synthetic analog of uroguanylin, has received FDA approval for the treatment of chronic idiopathic constipation and irritable ...

Bai T, Xu Z, Zhen Y, Liao A, Wang B, Zhao R et al.

Plecanatide is a novel guanylate cyclase-C agonist for the treatment of functional constipation (FC). Its efficacy may vary across different racial populations.This study aimed to comprehensively evaluate the efficacy, safety, and pharmacokinetics of plecanatide in Chinese patients with FC.This p...

Andrews MB, Adler DG

FDA approved treatments for constipation-predominant irritable bowel syndrome (IBS-C) include secretagogues (Linaclotide, Lubiprostone, and Plecanatide) and a retainagogue (Tenapanor). The FDA Adverse Event Reporting System (FAERS) database collects suspected medication-related adverse events (AE...

Busam JA, Batta N, Shah ED, Joo L, Marshall C, Rezaie A et al.

Understanding the safety of pharmacotherapy for irritable bowel syndrome (IBS) enables individuals to make informed treatment decisions. While many studies include the number needed to treat to highlight therapeutic benefits, adding the number needed to harm (NNH), a measure we evaluate herein, c...

Montastruc JL

Patient satisfaction is a key element in medical practice. Few studies have investigated patient satisfaction or dissatisfaction with their drug treatment.Using the World Health Organization (WHO) global pharmacovigilance database, we investigated, through disproportionality analyses, potential a...

Kim DH, Song HY, Nam K, Korean Society of Neurogastroenterology and Motility

Irritable bowel syndrome with predominant constipation (IBS-C) is a functional gastrointestinal disorder characterized by abdominal pain with chronic constipation and abdominal bloating, which could significantly impair the quality of life of patients and bring substantial socio-economic burdens....

Shah E, Lee TY, Baldwin Z, Kort J, Ando M, Champaloux SW et al.

Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are common functional intestinal disorders which impact all age groups, yet there is limited comparative evidence on the economic benefits of treatment of these conditions on the elderly. We assessed diff...

Zhang W, Wang H, Yang S, Pang X, Hu W, Zhang G et al.

Laxatives are widely used in the treatment of constipation, but they also have brought many adverse reactions to patients.We conducted a pharmacovigilance analysis based on the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database to analyze the adverse events...